Renin Release in Response to Renin System Blockade: Activation of the Renin System in Type 1 Diabetes Mellitus

Abstract

Activation of the renin-angiotensin system (RAS) in diabetes is thought to contribute to nephropathy. This is suggested by findings of an enhanced renovascular (RPF) response to RAS blockade with angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs). An alternative approach to assess RAS activation is the evaluation of renin release following RAS blockade.

Forty-four consecutively enrolled Type 1 diabetic patients (28.2 ± 1.5 years) and 37 normal subjects (37 ± 2.6 years) in high salt balance were given 25 mg of captopril and 16 mg of candesartan p.o. on consecutive days. All subjects were Caucasian. All, except one diabetic patient, had normal renal function. Plasma renin activity (PRA) and renal plasma flow (RPF) were measured for four hours after both drugs, and at eight, and 24 hours after candesartan.

As anticipated, both drugs increased PRA. Peak responses (90' after captopril) were 5.6 ± 1 ng/mL Ang I/hour in diabetic patients, and 1.7 ± 0.9 ng/mL Ang I/hour in normal subjects (p<0.001). Responses to both drugs were correlated in diabetic patients for PRA (r=0.623; p=0.001) and for RPF (r=0.9; p<0.001). When the PRA response to captopril was below the median, the RPF response was limited (22.1 ± 17.6 ml/minute/1.73 m²). When it was above the median, the RPF response was also larger (62.2 ± 13.9 ml/minute/1.73 m²; p=0.006).

Renin response to ACE-I and ARB confirms activation of the RAS in diabetic patients.

Keywords

Diabetes Renin Renal plasma flow

Get full access to this article

View all access options for this article.

References

Remuzzi G. , Ruggenenti P. , Perico N. Chronic Renal Diseases : Renoprotective Benefits of Renin-Angiotensin System Inhibition. Ann Intern Med 2002;136(8):604-15.

Brenner BM , Cooper ME , de Zeeuw D. et al. The losartan renal protection study -rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). JRAAS 2000;1(4):328-35.

Lewis EJ The role of Angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 2002;15(10 Pt 2):123S-128S.

Lansang MC , Price DA , Laffel LMB et al. Renal vascular responses to captopril and to candesartan in patients with Type 1 diabetes mellitus. Kidney Int 2001;59:1432-38.

Lohmeier TC The sympathetic Nervous System and Long -Term Blood Pressure regulation . Am J Hypertens 2001; 14:147S-154S.

Lansang MC , Hollenberg NK

Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: Are the forces leading to vasodilation and vasoconstriction linked?

Diabetes 2002;51:2025-28.

Gordon MS , Price DA , Hollenberg NK Blunted suppression of plasma renin activity in diabetes. JRAAS 2000; 1(3):252-6.

Price DA , Porter LE , Gordon MS et al. The Paradox of the Low-Renin State in Diabetic Nephropathy. J Am Soc Nephrol 1999;10:2382-91.

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Diabetes Care 2003;26: S1:S5-S20.

10.

Fischer M. , Baessler A. , Schunkert A. Renin angiotensin system and gender differences in the cardiovascular system . Cardiovasc Res 2002;53(3):672-7. 11. Hollenberg NK , Meggs LG , Williams GH , Katz J. , Garnic

11.

JD, Harrington DP Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int 1981;20:240-5.

12.

Lansang MC , Osei SY , Price DA , Fisher NDL , Hollenberg NK Renal Hemodynamic and Hormonal Responses to the Angiotensin II Antagonist Candesartan. Hypertension 2000; 36:834-8.

13.

Belminute J. , Levy BI , Michel JB : Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging 1994;5(5):391-400.

14.

Bauer JH Age-related changes in the renin-aldosterone system: physiological effects and clinical implications. Drugs Aging 1993 ;3(3):238-45.

15.

Hollenberg NK , Rivera A. , Meinking T. et al. Age, renal perfusion and function in island dwelling indigenous Kuna Amerinds of Panama. Nephron 1999;82(2):131-8.

16.

Osei SY , Price DA , Fisher NDL , Porter L. , Laffel LMB , Hollenberg NK Hyperglycemia and Angiotensin-Mediated Control of the Renal Circulation in Healthy Humans. Hypertension 1999;33(part II):559-64.

17.

Miller JA , Floras JS , Zinman B. , Skorecki KL Effect of hyperglycaemia on arterial pressure, plasma renin activity nd renal function in early diabetes. Clin Sci 1996;90: 189-95.

18.

Lansang MC , Osei SY , Coletti CM , Krupinski J. , Hollenberg NK Hyperglycemia-induced intrarenal RAS activation: the contribution of metabolic pathways. JRAAS 2002;3:19-23.

19.

Burns KD , Homma T. , Harris RC The intrarenal reninangiotensin system: Semin Nephrol 1993 ;13(1):13-30.

20.

De'Oliveira JM , Price DA , Fisher NDL et al. Autonomy of the renin system in type II diabetes mellitus: Dietary and renal hemodynamic responses to ACE inhibition . Kidney Int 1997 ;52:771-7.

21.

Hollenberg NK The kidney and angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists. In: Therapy in Nephrology and Hypertension, 2nd edition, Companion to Brenner and Rector's The Kidney. Edited by HR Brady and CS Wilcox , Philadelphia, WB Saunders, 2003, pp.547-54.